The portfolio maintains a cost advantage over competitors, priced within the lowest fee quintile among peers.
SPDR® S&P Pharmaceuticals ETF XPH
Morningstar’s Analysis XPH
Will XPH outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 48.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Intra-Cellular Therapies Inc | 5.34 | 10.1 Mil | Healthcare |
Merck & Co Inc | 5.07 | 9.6 Mil | Healthcare |
Perrigo Co PLC | 4.99 | 9.5 Mil | Healthcare |
Catalent Inc | 4.89 | 9.3 Mil | Healthcare |
Organon & Co Ordinary Shares | 4.81 | 9.1 Mil | Healthcare |
Pfizer Inc | 4.76 | 9.0 Mil | Healthcare |
Eli Lilly and Co | 4.75 | 9.0 Mil | Healthcare |
Jazz Pharmaceuticals PLC | 4.66 | 8.8 Mil | Healthcare |
Johnson & Johnson | 4.62 | 8.8 Mil | Healthcare |
Royalty Pharma PLC Class A | 4.62 | 8.8 Mil | Healthcare |